IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
Executive Summary
FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S
You may also be interested in...
IoM Drug Safety Report Recommends Sweeping Changes At CDER
FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a final report issued Sept. 22
IoM Drug Safety Report Recommends Sweeping Changes At CDER
FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a final report issued Sept. 22
FDA Gets Permanent Drug Safety Director In Advance Of Drug Center Overhaul
FDA's Office of Drug Safety will take on a higher profile position under a proposed reorganization of the Center for Drug Evaluation & Research